By Dave Sebastian

Sage Therapeutics Inc. said it has gotten a fast-track designation from the Food and Drug Administration for its Sage-718 drug candidate to be developed as potential treatment for Huntington's disease.

The fast track is a process for facilitating the development and review of new treatments for severe conditions.

Sage said it expects to start a Phase 2 trial with the drug candidate in early to moderate Huntington's disease in late 2021.

Huntington's disease is a rare, inherited neurodegenerative disease, Sage said. As many as 30,000 adults are diagnosed with the disease in the U.S. each year, the company said.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

September 15, 2021 06:59 ET (10:59 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Sage Therapeutics Charts.
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Sage Therapeutics Charts.